Oxford BioTherapeutics Appoints Michael Moore as Chairman
Published In: Business, United Kingdom 
Wednesday, December 9, 2009 4:00 AM
< Archive for Sep 2010 >
SuMoTuWeThFrSa
   1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
OXFORD, England, December 9 /PRNewswire/ --

- Appointment Follows Recent Recruitment of Senior Antibody Industry
Leaders and Highlights OBT's Growth Into a Leading Oncology-Focused
Therapeutic Antibody Company

Oxford BioTherapeutics (OBT) has today announced the appointment of Dr
Michael Moore as non-executive Chairman. Dr Moore brings considerable
expertise and experience to OBT at an exciting phase in the Company's
development, as it capitalises on partnerships with GSK, Amgen, Medarex and
Biosite to build a broad pipeline of therapeutic antibodies in oncology.

Dr Moore has several decades of senior management experience in the
biotechnology sector and joins the Board of OBT following five years at UK
biotechnology company, Piramed Limited, where he was CEO until its
acquisition by Roche in 2008. Prior to joining Piramed, Dr Moore was CSO and
Research Director of Xenova Group plc. During a distinguished career he has
also held senior academic positions at the Paterson Institute for Cancer
Research, Christie Hospital, Manchester, UK and the Brunel Institute of
Cancer Genetics and Pharmacogenomics where he is still Professor Associate.

Today's announcement follows OBT's recent recruitment of a number of
other senior industry leaders in the biologics field and heralds another
important milestone for the Company, as it matures into a global leader in
the rapidly developing oncology therapeutic antibody sector. The company
recently announced the appointment of Jim Cornett, Chief Operating Officer,
Mike Gresser, Chief Scientific Officer, and Jon Terrett, VP Oncology, to lead
its US R&D operations.

Dr Moore commented, "I am delighted to join Oxford BioTherapeutics at
this exciting time in the Company's development. I have been highly impressed
by OBT's scientific and commercial approach and am very pleased to join the
other distinguished members of the OBT Board and management, as we work
together to set the strategic framework for the Company's continued growth
and success."

Oxford BioTherapeutics' CEO, Dr Christian Rohlff, welcomed Michael to the
Company, commenting, "I am delighted that a biotechnology industry veteran
who has made such a distinguished contribution to the field of targeted drug
discovery has agreed to join the OBT board. I have no doubt that Michael will
bring great value to the Company by virtue of his considerable experience and
track record at successful and innovative companies in the sector."

OBT's impressive target discovery and therapeutic antibody capabilities
led to a recent partnership with GSK which was announced in May 2009. The GSK
partnership is focused on the discovery, development and commercialisation of
novel, therapeutic antibodies for the treatment of primary, metastatic and
recurring forms of cancer.

OBT's antibody programs involve novel therapeutic targets that were
discovered using the Company's proprietary OGAP(R) database. The Company's
recent rapid progress is based on its unique in-house capabilities in the
discovery of novel targets for oncology combined with the expertise of its
partners, Medarex and Amgen, in the development of antibody therapeutics to
create an exciting pipeline of innovative first-in-class therapeutics for the
treatment of cancer. Through these collaborations, OBT has access to the two
leading technologies for generating fully human monoclonal antibodies.

In addition, OBT collaborates with Biosite Inc., a wholly owned
subsidiary of Inverness Medical Innovations, for the identification of novel
protein-based disease markers for several cancer indications and for the
development of companion diagnostic products aimed at improving the
diagnosis, prognosis and treatment options for patients with cancer.

Michael Moore

Dr Moore was most recently Chief Executive Officer and Director of
Piramed Ltd, a UK-based biotechnology company focused on the discovery and
development of small molecule drugs targeting specific isoforms of the PI3
kinase super-family for cancer and immune-inflammatory disease. Piramed
concluded a major collaboration with Genentech in November 2005 and the
company was acquired by F Hoffmann-La Roche in an all-share transaction in
May 2008. He is also Associate Professor at the Brunel Institute of Cancer
Genetics and Pharmacogenomics, a post he has held since 1997. Prior to
joining Piramed, Dr Moore held several progressive positions at Xenova Group
plc (1988-2003), including Chief Scientific Officer and Research Director. He
held a tenured Cancer Research Campaign Special Appointment at the Paterson
Institute for Cancer Research, Christie Hospital, Manchester from 1980-1988,
was Honorary Reader in Immunology and Oncology at the University of
Manchester Medical School from 1986-1988, and Editor-in-Chief of the British
Journal of Cancer from 1983-1988. Dr. Moore received his PhD (Faculty of Pure
Science) and DSc (Faculty of Medicine) from Nottingham University and has
more than 150 scientific publications. He is a Fellow of the Royal College of
Pathologists.

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is focused on the development of targeted
antibody medicines for oncology. OBT's strategy is to develop innovative
antibody-based cancer drugs, with integrated diagnostics, against novel
targets that it has discovered in its unique OGAP(R) proteomic database. OBT
is in an unrivalled position to convert its novel targets into a successful
therapeutic pipeline through its alliances with the world leaders in antibody
development (Medarex, Biosite and Amgen). OBT's current antibody pipeline is
expected to deliver innovative and cost-effective medicines to fulfil major
unmet patient needs in the field of cancer. OBT, a privately held company,
was formed in 2004 and is based near Oxford, UK.

For further information, please see http://www.OxfordBioTherapeutics.com

For further information, please contact:

Oxford BioTherapeutics

Dr Christian Rohlff
Chief Executive Officer
Tel: +44(0)1235-861770
cr@oxbt.co.uk

Citigate Dewe Rogerson
David Dible, Amber Bielecka
Tel: +44(0)207-638-9571
david.dible@citigatedr.co.uk




SOURCE Oxford BioTherapeutics (OBT)


 
Wednesday, December 9, 2009 4:00 AM

Share Socially:
BlinkListBlinkList del.icio.usdel.icio.us DiggDigg FurlFurl ma.gnoliama.gnolia redditreddit SimpySimpy SpurlSpurl BlogMarksBlogMarks NewsvineNewsvine Share on Facebook Sphere: Related Content

Related Press Releases

Michael Moore Unveils Title for New Film
Published In: Business, California 
Thursday, July 9, 2009 3:01 AM
***CALL TOMORROW 2/22 WITH MICHAEL MOORE, SICKO PATIENTS***
Published In: California, Entertainment 
Thursday, February 21, 2008 8:03 PM
Meaden & Moore Welcomes A. Michael Nuzzo to The Wealth Center
Published In: Business, Ohio 
Wednesday, January 13, 2010 9:39 AM
Contact Us | Terms of Use | Trademarks | Privacy Statement
(c) 2008-2009 Press Related